CAMBRIDGE, Mass.-based Aileron Therapeutics, a biopharmaceutical company that has developed a new class of drugs called stapled peptides, has appointed Anthony M. Manning, Ph.D., to senior vice president of research and preclinical development and Yong S. Chang, Ph.D., to head of biology.
Manning has more than 19 years of industry experience in advancing drug discovery projects and multiple therapeutic candidates through preclinical and clinical development. Manning has served as vice president and head of inflammation and autoimmune diseases research at Biogen Idec. He also held other senior level R&D positions within the company.
Chang joins Aileron from MedImmune where he was the head of translational pharmacology. At MedImmune, he was one of the senior members of the global oncology leadership team and research review committee, and he also led multiple translational and product development teams. Prior to MedImmune, he worked with Bayer Pharmaceuticals.